Genomic Health
Discover the strength of evidence supporting genomic testing in breast cancer and what that means for your patients.

Chair: Norman Wolmark, USA

Introduction and the story so far: What makes a clinically useful assay?

Norman Wolmark, USA

Reviewing the evidence of clinical utility of genomic testing in patients with node-negative, ER+ breast cancer

Christy Russel, USA

A review of prospective trial and outcomes data evaluating the performance of genomic testing in patients with node-positive, ER+ breast cancer

Christian Jackisch, Germany

Multigene assays in breast cancer – do they all tell you the same thing?

Joseph Gligorov, France

 Predicting late recurrence risk 

 Norman Wolmark, USA